Pharmaceutical Technology

SEPTEMBER 13, 2022

The acquisition will expand the international solutions portfolio of AmerisourceBergen aiding in advancing its position as a preferred partner for biopharmaceutical manufacturers. This approach will support its manufacturer partners throughout the pharmaceutical development and marketing processes.

Manufacturing 130

Manufacturing Compliance Marketing Clinical Development 130

XTalks

OCTOBER 22, 2020

The information shared between different multidisciplinary teams is critical to reducing the cost and ultimately accelerating the path of bringing a drug to market. To achieve transparency and actionability of data, pharmaceutical companies are evolving their manufacturing processes by digitalizing the data from all of their equipment.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

The Pharma Data

SEPTEMBER 22, 2020

Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This guidance provides clarity on the path to registration for AVXS-101 IT.

Clinical Development 52

Clinical Development Gene Therapy Development Gene 52

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. It was under development for the treatment of small-cell lung cancer, cholangiocarcinoma, small-cell lung cancer, urothelial cell cancer and endometrial cancer.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Delveinsight

MARCH 1, 2021

Thus, it can be conveniently said that the Rare disease market, which was once barren land has now become fertile ground. First and foremost, the regulatory agencies were ready and willing, with ornaments in hand to decorate the Rare disease market with novel therapies. While more than 150 orphan drugs have been approved in the EU.

Marketing 52

Marketing Clinical Trials Clinical Trials Drugs 52

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1.

Clinical Development 52

Clinical Development Medicine Development Containment 52

Pharmaceutical Technology

FEBRUARY 20, 2023

BI-685509 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Systemic Sclerosis (Scleroderma). It operates facilities for manufacture pharmaceuticals and medical products. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. Novo Nordisk overview Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Roots Analysis

FEBRUARY 3, 2023

It is also worth highlighting that there are a significant number of cell therapies that are currently under clinical development. Several industry players (XX) are actively contributing to the manufacturing and development of cell therapies in North America, Europe and Asia Pacific regions. It is just a click away.

Manufacturing 40

Manufacturing Gene Therapy Marketing Gene 40

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. . ” About Ascletis.

Clinical Development 40

Clinical Development Development Clinical Trials Clinical Trials 40

Pfizer

SEPTEMBER 16, 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union. Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Melanoma. Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The therapeutic candidate acts by targeting diacylglycerol kinase zeta.

Clinical Trials 130

Clinical Trials Clinical Trials Drugs Clinical Development 130

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Solid Tumor. Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The therapeutic candidate acts by targeting diacylglycerol kinase zeta.

Clinical Trials 130

Clinical Trials Clinical Trials Drugs Clinical Development 130

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

JUNE 5, 2023

BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hypopharyngeal Cancer. It operates facilities for manufacture pharmaceuticals and medical products. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Roots Analysis

FEBRUARY 28, 2023

Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Roots Analysis

FEBRUARY 26, 2024

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Non-Small Cell Lung Carcinoma. Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals.

Clinical Trials 130

Clinical Trials Clinical Trials Drugs Clinical Development 130

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Manufacturing 52

Manufacturing Gene Therapy Trials Gene 52

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. Rituximab biosimilar is under development for the treatment of previously untreated follicular lymphoma and rheumatoid arthritis in the U.S

Production 100

Production DNA Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products. It is a hydroxamate.

Production 100

Production Manufacturing Drugs Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products.

Production 100

Production Manufacturing Drugs Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products. It is a hydroxamate.

Production 100

Production Manufacturing Drugs Development 100

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Manufacturing 52

Manufacturing Vaccination Vaccine Clinical Trials 52

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept.

Clinical Development 40

Clinical Development Medicine Development Production 40

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Solid Tumor. Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The therapeutic candidate is a small molecule acts by targeting KRAS G12D.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Clinical Development 100

XTalks

MAY 30, 2024

Then, one must collaborate with regulatory affairs, data management, nonclinical, CMC [chemistry, manufacturing and controls], clinical development, medical affairs medical writing and others. “I see pharmacovigilance in the center of everything. So, there are lots of pieces to it,” he adds.

Compliance 105

Compliance Clinical Development Pharmacy Development 105

Delveinsight

NOVEMBER 29, 2020

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

JANUARY 2, 2023

BI-1361849 is under clinical development by Boehringer Ingelheim International and currently in the Phase II in clinical pathway. It operates facilities for manufacture pharmaceuticals and medical products. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals.

Drugs 100

Drugs Production Manufacturing Development 100

Pharmaceutical Technology

JULY 7, 2022

While just two gene therapy products have been approved by the FDA, a number of companies are nearing the market with therapies targeting rare diseases, including 14 candidates in Phase III plus three in the pre-registration phase, according to GlobalData. A new frontier in cancer research. Securing the supply chain.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

XTalks

NOVEMBER 28, 2023

The biosimilar industry today is marked by rapid advancements, regulatory evolution and growing market acceptance. Featuring Ilsun Hong, VP and Product Evaluation Team Leader, and Thomas Newcomer, VP and Head of US Market Access at Samsung Bioepis, the discussion revolves around key developments, challenges and future trends in biosimilars.

Production 98

Production Marketing Development Pharmacy 98